Drug­mak­ers cut prices on av­er­age by more than 60% to get on Chi­na's 2022 NDRL list — re­port

Chi­na’s Na­tion­al Re­im­burse­ment Drug List (NRDL) is a crys­tal clear ex­am­ple of the coun­try’s bar­gain­ing pow­er in the biotech and phar­ma mar­ket, as more firms …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER